Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Christine Orsini"'
Autor:
Florence Joly, Christophe Le Tourneau, Christine Orsini, Emmanuelle Bompas, Pierre Fumoleau, Thomas Bachelot, Véronique Diéras, Etienne Chatelut, Marta Jimenez, Sabine Noal, Nicolas Isambert, Diane Charlotte Imbs, Mario Campone, Philippe A. Cassier
Publikováno v:
Oncology and Therapy
Introduction To determine the feasibility, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT) of pazopanib in combination with cisplatin. Methods Patients with advanced malignancies were included in a 3 + 3 dose-escalation phase I study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::748ef9264388d2dca06141f41408aff8
http://europepmc.org/articles/PMC5315079
http://europepmc.org/articles/PMC5315079
Autor:
Christine Orsini
Publikováno v:
Que sais-je ? ISBN: 9782130798767
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::690a1414a2704c4b01fd1c4d77f261d7
https://doi.org/10.3917/puf.orsin.2018.01
https://doi.org/10.3917/puf.orsin.2018.01
Autor:
Philippe Quetin, Claire Chara-Bruneau, Hugo Marsiglia, Yazid Belkacemi, Jean-Michel Hannoun-Levi, Etienne Brain, Christine Orsini, Sophie Gourgou-Bourgade, Christophe Hennequin
Publikováno v:
Brachytherapy. 12(4)
To analyze the feasibility, reproducibility, and impact on functional status of postoperative accelerated and partial breast irradiation (APBI) using interstitial high-dose rate-brachytherapy in women older than 70 years.From July 2004 to April 2008,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bddcb12dcb70c3272085e0822bd43fc8
https://pubmed.ncbi.nlm.nih.gov/23415050
https://pubmed.ncbi.nlm.nih.gov/23415050
Autor:
E. Malaurie, Christine Orsini, Nicole Tubiana-Mathieu, Claudia Lefeuvre, D. Allouache, Emmanuelle Bourbouloux, Franck Bonnetain, Florence Rollot, Hervé Curé, Emmanuel Blot, Paul Cottu, Jean-Marc Ferrero, Olivier Mir, Etienne Brain, Sylvie Kirscher, Coraline Dubot, Gilles Romieu, Olivier Rigal, Magali Lacroix-Triki, Hélène Peyro-Saint-Paul
Publikováno v:
Cancer Research. 75:OT3-3
The benefit of adjuvant chemotherapy (CT) added to hormonal therapy (HT) compared with HT alone remains debated for women >70 with ER+ HER2- breast cancer (BC). Selection of valid indications might be improved by the use of better prognosticator. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bad9bcee1f6f194186e8b9528ff490b
https://doi.org/10.1158/1538-7445.sabcs14-ot3-3-02
https://doi.org/10.1158/1538-7445.sabcs14-ot3-3-02
Autor:
Frédérique Rousseau, O. Rigal, Veronique Girre, Emmanuelle Fourme, S. Abadie-Lacourtoisie, Isabelle Turbiez, Christine Orsini, C. Mertens, Etienne Brain, Lionel Uwer
Publikováno v:
Journal of Geriatric Oncology. 4:S26-S27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd18658afcb528fdc3d233ce18436107
https://doi.org/10.1016/j.jgo.2013.09.010
https://doi.org/10.1016/j.jgo.2013.09.010
Autor:
Aurélien Latouche, M. Lacroix-Triki, Sandrine Baffert, Veronique Girre, O. Rigal, Christine Orsini, Paul-Henri Cottu, Franck Bonnetain, H. Peyro Saint-Paul, Etienne Brain, Emmanuelle Bourbouloux, Florence Rollot, Hervé Curé, Gilles Romieu, V. Servent, J.-M. Ferrero, Hervé Bonnefoi, C. Léger-Falandry
Publikováno v:
Journal of Geriatric Oncology. 3:S34-S35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5138a283dd48d6a0e13d7b14b0fd43d3
https://doi.org/10.1016/j.jgo.2012.10.005
https://doi.org/10.1016/j.jgo.2012.10.005
Autor:
Nicole Tubiana-Mathieu, Sylvie Kirscher, H. Peyro-saint-paul, Gilles Romieu, Olivier Mir, Etienne Brain, Olivier Rigal, M. Lacroix-Triki, Emmanuel Blot, D. Allouache, Emmanuelle Bourbouloux, Coraline Dubot, Florence Rollot, Hervé Curé, Paul-Henri Cottu, J.-M. Ferrero, Franck Bonnetain, C. Lefeuvre, E. Malaurie, Christine Orsini
Publikováno v:
Journal of Geriatric Oncology. 5:S28
adjuvant chemotherapy (aCT) and adjuvant hormonal therapy (aHT) of newly-diagnosed patients with early-stage breast cancer. Methods: Participants included patients diagnosed with stages I–II disease, aged 40 years or older at diagnosis. Patients we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bd1804f582bdd10d925edb888d85ee4
https://doi.org/10.1016/j.jgo.2014.09.039
https://doi.org/10.1016/j.jgo.2014.09.039
Autor:
Emmanuelle Bourbouloux, Sophie Abadie-Lacourtoisie, Hervé Curé, Y. Tazi, Emmanuel Blot, E. Malaurie, Paul-Henri Cottu, HP Peyro Saint Paul, Christine Orsini, M. Triki Lacroix, Franck Bonnetain, D. Allouache, J-M Ferrero, Olivier Rigal, Florence Rollot, Etienne Brain, Catherine Terret, Sylvie Kirscher, Gilles Romieu, Coraline Dubot
Publikováno v:
Annals of Oncology. 25:iv108
Background: Benefit of the additional adjuvant chemotherapy (CT) compared with hormonal therapy alone (HT) remains debated for women >70 with ER+ HER2- breast cancer (BC) and aggressive characteristics. This trial compares the impact of both strategi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fea8b64ee22ab0eff85769e9cc4a6e05
https://doi.org/10.1093/annonc/mdu327.75
https://doi.org/10.1093/annonc/mdu327.75
Autor:
Ivan Bièche, Olivier Malard, Jérôme Fayette, Christophe Le Tourneau, Christine Orsini, Frederic Peyrade, Gilles Dolivet, Nicolas Aide, Leanne De Koning, Odette Mariani, Jean-Pierre Delord, Jerzy Klijanienko, Laurent Laccourreye, Frederic Rolland, Xavier Paoletti, Olivier Capitain, Dominique De Raucourt, Xavier Sastre, Stéphane Temam
Publikováno v:
Journal of Clinical Oncology. 32:TPS6105-TPS6105
TPS6105 Background: Identification of efficacy predictive biological biomarkers in HNSCC patients treated with anti-EGFR targeted therapy is still a challenge. In the recurrent/metastatic setting, sequential biopsies allowed correlating potential pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee2863ac3b804f79c8abad0f514d9050
https://doi.org/10.1200/jco.2014.32.15_suppl.tps6105
https://doi.org/10.1200/jco.2014.32.15_suppl.tps6105
Autor:
Emmanuel Sevin, Corinne Sarda, Emmanuelle Bompas, Nadine Houede, Gwenaelle Gravis, Frank Priou, Sophie Abadie Lacourtoisie, Loic Mourey, Igor Latorzeff, Thomas Filleron, Christine Orsini, Elisabeth Carola
Publikováno v:
Journal of Clinical Oncology. 32:152-152
152 Background: Chemotherapy with docetaxel-prednisone (DP) is one of the standard treatment of castration-resistant metastatic prostate cancer (CRMPC). However little is known about feasibility of DP in frail elderly patients seen in daily practice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8568ecfb4a142476157ffb5ae5ff822d
https://doi.org/10.1200/jco.2014.32.4_suppl.152
https://doi.org/10.1200/jco.2014.32.4_suppl.152